GSK Archives

News and Trends 13 Jun 2022

GSK positive on RSV vaccine for older adults

GSK plc has announced positive headline results from its AReSVi 006 phase III trial. AReSVi 006 is a phase III trial investigating GSK’s respiratory syncytial virus (RSV) vaccine candidate for adults aged 60 years and above. GSK said no unexpected safety concerns were observed. Dr Hal Barron, chief scientific officer and president, R&D, GSK, said, […]

June 13, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 2 Jun 2022

Upstream Bio to target asthma as it launches with $200M financing

Upstream Bio, a U.S. biotech company focused on inflammation, today exited stealth mode with $200M Series A financing. The company said the funding will allow it to advance its lead program UPB-101, a clinical-stage monoclonal antibody targeting the thymic stromal lymphopoietin (TSLP) receptor. It added the investment will also help build a pipeline of assets […]

June 2, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 1 Jun 2022

GSK to acquire clinical-stage biopharmaceutical company Affinivax

GSK plc is set to acquire Affinivax, Inc., a clinical-stage biopharmaceutical company based in Cambridge, Boston, Massachusetts, for a $2.1B upfront payment and up to $1.2B in potential development milestones. Affinivax is developing a novel class of vaccines, the most advanced of which are next-generation pneumococcal vaccines. Pneumococcal disease includes pneumonia, meningitis, bloodstream infections, and […]

June 1, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 30 Jun 2021

GSK Raises Eyebrows in Checkpoint Inhibitor Megadeal with iTeos

Analysts are abuzz over GSK’s co-development deal with immuno-oncology specialist iTeos Therapeutics earlier this month, wondering if it overpaid for the Belgian company’s next-generation checkpoint inhibitor. GSK’s oncology deal with iTeos earlier this month centered on an antibody drug that blocks an immune checkpoint called TIGIT. The candidate is currently in phase I testing for […]

June 30, 2021 - 5 minutesmins - By Victor Kotsev

News and Trends 15 Jan 2021

GSK Acne Deal Heralds Growing Interest in Skin Microbiome

This week, the Paris-based Eligo Bioscience became one of a growing number of biotechs to land a big pharma deal focused on the skin microbiome, receiving up to €185M from GlaxoSmithKline (GSK) as they explore a CRISPR-based treatment for acne. Acne is a condition that troubles the majority of adolescents and often persists into adulthood. […]

January 15, 2021 - 4 minutesmins - By Kostas Vavitsas

News and Trends 23 Jul 2020

Pharma Giant GSK and mRNA Biotech CureVac Ink €1B Deal

GlaxoSmithKline (GSK) has struck a deal worth up to €1B with the German biotechnology company CureVac to co-develop messenger RNA drugs for infectious diseases. Under the terms of the deal, GSK will fund the development and manufacturing of up to five mRNA-based vaccines and antibody drugs targeting undisclosed infectious diseases. CureVac’s current rabies and Covid-19 […]

July 23, 2020 - 3 minutesmins - By David Wilson

News and Trends 23 Mar 2020

ViiV Healthcare’s Monthly HIV Injection Gains First Approval in Canada

A monthly two-drug injection developed by the GSK spinoff ViiV Healthcare has been approved for the treatment of HIV in Canada, which could replace the need for daily antiretroviral pills. The treatment — branded as Cabenuva and developed in collaboration with Janssen — was approved by Health Canada to suppress HIV in adults with stable […]

March 23, 2020 - 2 minutesmins - By Jonathan Smith

News and Trends 25 Feb 2020

Update: Janssen and Maze Jump on Board Finnish Genomics Project

Update (25/02/2020): Janssen and the US company Maze Therapeutics are the latest pharma companies to sign up as partners in the public-private genomics collaboration FinnGen. FinnGen’s pharma partners now total 11, including Sanofi and GSK, which joined early last year. Published 23/01/2019: Sanofi and GSK have joined up with a project collecting genomic and health […]

February 25, 2020 - 3 minutesmins - By Jonathan Smith

News and Trends 20 Feb 2020

Immatics Partners GSK in Deal Worth €1B to Develop Cancer Therapies

The German biotech Immatics will partner with GSK and could receive more than €1B from the big pharma for developing cancer immunotherapies based on engineered immune T-cells. Immatics will collaborate with GSK to develop two T-cell therapies that express a protein engineered to detect cancer antigens and kill cancer cells. In return, Immatics will receive […]

February 20, 2020 - 3 minutesmins - By Jonathan Smith

News and Trends 22 Nov 2019

ViiV Healthcare Licenses Long-Acting Antibody to Attack Hidden HIV

The UK company ViiV Healthcare will begin a phase IIa trial of an antibody licensed from the National Institutes of Health in the US that could block HIV transmission for longer than current antiretroviral therapies. The antibody is currently in an ongoing phase I trial run by the National Institute of Allergy and Infectious Diseases, […]

November 22, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 31 Oct 2019

European Project Launches to Tailor Autoimmune Disease Treatments

Public and private organizations across Europe will pool their resources in an €80M project to discover biomarkers that can predict which patients will respond best to treatments for autoimmune diseases. The project is called Taxonomy, Treatments, Targets and Remission, or 3TR for short, and is funded by the EU’s Innovative Medicines Initiative for the next […]

October 31, 2019 - 2 minutesmins - By Jonathan Smith

Expert Advice 7 Aug 2019

Why Making the Jump from Pharma to Biotech Can be a Life Changing Experience

In less than two years, Orchard Therapeutics has changed from a small, relatively unknown UK biotech specializing in gene therapy into a billion euro company listed on the Nasdaq. This is in no small part due to the skills and experience of Mark Rothera, its CEO and President, who joined the company in 2017. Orchard […]

August 7, 2019 - 13 minutesmins - By Helen Albert

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us